Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07476729 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

Name: International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) — clinical trial record (NCT07476729)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorCharite University, Berlin, Germany

Started2026-04-01

View on ClinicalTrials.gov ↗

Charite University, Berlin, Germany

132 trials monitored

See 2 trials at risk

Leukemia

2,553 trials monitored

See 134 trials at risk

Acute Lymphoblastic Leukemia (ALL)

873 trials monitored

See 52 trials at risk

The IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as replacements for toxic SOC chemotherapy elements. The IntReALL BCP 2020 study has the potential to improve CR and EFS rates for all SR and HR groups, as well as for patients with IEM recurrence, by replacing toxic chemotherapy with targeted, less toxic immunotherapy strategies, and could establish these new approaches as SOC for children with relapsed BCP ALL in the future.

Trial Details

NCT Number	NCT07476729
Lead Sponsor	Charite University, Berlin, Germany
Conditions	B-Cell Acute Lymphoblastic Leukaemia
Enrollment	750 participants
Start Date	2026-04-01
Primary Completion	2033-03-31 (estimated)
Study Completion	2033-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-17